首页 » 文章 » 文章详细信息
Journal of Oncology Volume 2019 ,2019-09-26
IL-2 Induces Transient Arrest in the G1 Phase to Protect Cervical Cancer Cells from Entering Apoptosis
Research Article
María del Carmen Lagunas-Cruz 1 Arturo Valle-Mendiola 1 Jonathan Trejo-Huerta 1 Leticia Rocha-Zavaleta 2 María de Lourdes Mora-García 1 Adriana Gutiérrez-Hoya 1 , 3 Benny Weiss-Steider 1 Isabel Soto-Cruz 1
Show affiliations
Received 2019-03-23, accepted for publication 2019-08-04, Published 2019-08-04

Interleukin 2 (IL-2) has been used for the treatment of different types of cancer that express the IL-2 receptor (IL-2R). However, the effect of IL-2 on cervical cancer cells is unknown. IL-2R is present in normal cells of the immune system but not in the healthy cervix. We report that IL-2R is expressed in cervical cancer cells. IL-2 decreases cervical cancer cell proliferation via transient arrest of the G1 phase, which does not result in apoptosis or senescence. IL-2 upregulates the expression of p53 and p21 and downregulates cyclin D. In addition, we report the resistance of cervical cancer cells to treatments that induce apoptosis in HeLa and INBL cells. When arrested cells were treated with cisplatin, the cytokine protected cells from apoptosis induced by cisplatin. The effects of IL-2 on the cell cycle do not induce cellular senescence or activate the proapoptotic protein Bax. The cell arrest induced by IL-2 is conferring protection to cells against apoptosis.


Copyright © 2019 María del Carmen Lagunas-Cruz et al. 2019
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Isabel Soto-Cruz.Molecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, CP 09230 Mexico City, Mexico, unam.mx.sotocruz@unam.mx


María del Carmen Lagunas-Cruz,Arturo Valle-Mendiola,Jonathan Trejo-Huerta,Leticia Rocha-Zavaleta,María de Lourdes Mora-García,Adriana Gutiérrez-Hoya,Benny Weiss-Steider,Isabel Soto-Cruz. IL-2 Induces Transient Arrest in the G1 Phase to Protect Cervical Cancer Cells from Entering Apoptosis. Journal of Oncology ,Vol.2019(2019)



[1] A. L. Andres, X. Gong, K. Di, D. A. Bota. et al.(2014). Low-doses of cisplatin injure hippocampal synapses: a mechanism for “chemo” brain?. Experimental Neurology.255(1):137-144. DOI: 10.3322/caac.20107.
[2] S. H. Park, E. K. Cho, S. M. Bang, D. B. Shin. et al.(2005). Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial. BMC Cancer.5(1):1-6. DOI: 10.3322/caac.20107.
[3] S. C. Righetti, G. Della Torre, S Pilotti. (1996). A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Research.56(4):689-693. DOI: 10.3322/caac.20107.
[4] K. H. Vousden, C. Prives. (2009). Blinded by the light: the growing complexity of p53. Cell.137(3):413-431. DOI: 10.3322/caac.20107.
[5] T. Soussi, K. G. Wiman. (2007). Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell.12(4):303-312. DOI: 10.3322/caac.20107.
[6] M. Ishikawa, K. Nakayama, M. T. Rahman. (2014). Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report. European Journal of Gynaecological Oncology.35(4):443-448. DOI: 10.3322/caac.20107.
[7] S. W. Lowe. (1999). Activation of p53 by oncogenes. Endocrine-Related Cancer.6(1):45-48. DOI: 10.3322/caac.20107.
[8] A. B. Niculescu, X. Chen, M. Smeets, L. Hengst. et al.(1998). Effects of p21 at both the G/S and the G/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endo reduplication. Mol Cell Biol.18(1):629-643. DOI: 10.3322/caac.20107.
[9] C. Bertoli, J. M. Skotheim, R. A. M. de Bruin. (2013). Control of cell cycle transcription during G1 and S phases. Nature Reviews Molecular Cell Biology.14(8):518-528. DOI: 10.3322/caac.20107.
[10] E. S. Wenzel, A. T. K. Singh. (2018). Cell-cycle checkpoints and aneuploidy on the path to cancer. In Vivo.32(1):1-5. DOI: 10.3322/caac.20107.
[11] R. Brown, C. Clugston, A. Edlin. (1993). Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. International Journal of Cancer.55(4):678-684. DOI: 10.3322/caac.20107.
[12] R. Arriagada, B. Bergman, A. Dunant, T. Le Chevalier. et al.(2004). International adjuvant lung cancer trial collaborative group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. The New England Journal of Medicine.350(4):351-360. DOI: 10.3322/caac.20107.
[13] X. Le, E. Y. Hanna. (2018). Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined. Annals of Translational Medicine.6(11):229. DOI: 10.3322/caac.20107.
[14] O. C. Rodriguez, S. Choudhury, V Kolukula. (2012). Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle.11(23):4436-4446. DOI: 10.3322/caac.20107.
[15] S. Elmore. (2007). Apoptosis: a review of programmed cell death. Toxicologic Pathology.35(4):495-516. DOI: 10.3322/caac.20107.
[16] K. J. Barnum, M. J. O’Connell. (2014). Cell cycle regulation by checkpoints. Methods in Molecular Biology.1170:29-40. DOI: 10.3322/caac.20107.
[17] C. F. Harrington, R. C. Le Pla, G. D. Jones, A. L. Thomas. et al.(2010). Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry. Chemical Research in Toxicology.23(8):1313-1321. DOI: 10.3322/caac.20107.
[18] J. Bubeník, J. Símová, D. Bubeníková, J. Zeuthen. et al.(1993). Utilization of interleukin-2 gene transfer in local immunotherapy of cancer. Journal of Cancer Research and Clinical Oncology.119(5):253-256. DOI: 10.3322/caac.20107.
[19] K. Barnouin, M. L. Dubuisson, E. S Child. (2002). HO induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21 expression. Journal of Biological Chemistry.277(16):13761-13770. DOI: 10.3322/caac.20107.
[20] M. A. Wasik, I. Nowak, Q. Zhang, L. M. Shaw. et al.(1998). Suppression of proliferation and phosphorylation of Jak3 and STAT5 in malignant T-cell lymphoma cells by derivatives of octylamino-undecyl-dimethylxanthine. Leukemia & Lymphoma.28(5-6):551-560. DOI: 10.3322/caac.20107.
[21] J. R. Caceres, J. A. Alvarado, K. Waga. (2001). Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias. Cancer Research.61(16):6281-6289. DOI: 10.3322/caac.20107.
[22] W. Gu, R. G. Roeder. (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell.90(4):595-606. DOI: 10.3322/caac.20107.
[23] L. Rössig, A. S. Jadidi, C. Urbich, C. Badorff. et al.(2001). Akt-dependent phosphorylation of p21 regulates PCNA binding and proliferation of endothelial cells. Molecular and Cellular Biology.21(16):5644-5657. DOI: 10.3322/caac.20107.
[24] C. Ciacci, Y. R. Mahida, A. Dignass, M. Koizumi. et al.(1993). Functional interleukin-2 receptors on intestinal epithelial cells. Journal of Clinical Investigation.92(1):527-532. DOI: 10.3322/caac.20107.
[25] H. C. Reinecker, D. K. Podolsky. (1995). Human intestinal epithelial cells express functional cytokine receptors sharing the common gamma c chain of the interleukin 2 receptor. Proceedings of the National Academy of Sciences.92(18):8353-8357. DOI: 10.3322/caac.20107.
[26] S. A. Rosenberg, J. R. Yannelli, J. C. Yang. (1994). Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. JNCI Journal of the National Cancer Institute.86(15):1159-1166. DOI: 10.3322/caac.20107.
[27] A. Karimian, Y. Ahmadi, B. Yousefi. (2016). Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair.42(1):63-71. DOI: 10.3322/caac.20107.
[28] L. S. Wang, K. C. Chow, W. Y. Li, C. C. Liu. et al.(2000). Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma. Clinical Cancer Research.6(4):1445-1451. DOI: 10.3322/caac.20107.
[29] F. Granucci, I. Zanoni, S. Feau, C. P. Ricciardi. et al.(2003). NEW EMBO MEMBER’S REVIEW: dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. The EMBO Journal.22(11):2546-2551. DOI: 10.3322/caac.20107.
[30] J. Buben`Ik. (1993). IL-2 gene therapy of cancer: at its beginning. Folia Biologica.39(6):279-288. DOI: 10.3322/caac.20107.
[31] S. D. Voss, P. M. Sondel, R. J. Robb. (1992). Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R. Journal of Experimental Medicine.176(2):531-541. DOI: 10.3322/caac.20107.
[32] C. Deng, P. Zhang, J. W. Harper, S. J. Elledge. et al.(1995). Mice lacking p21 undergo normal development but are defective in G1 checkpoint control. Cell.82(4):675-684. DOI: 10.3322/caac.20107.
[33] N. R. Arenas, J. Woytschak, O. Boyman. (2015). Interleukin-2: biology, design and application. Trends in Immunology.36(12):763-777. DOI: 10.3322/caac.20107.
[34] A. Valle, B. Weiss, L. Rocha, I. Soto. et al.(2014). IL-2 enhances cervical cancer cells proliferation and JAK3/STAT5 phosphorylation at low doses, while at high doses IL-2 has opposite effects. Cancer Investigation.32(4):115-125. DOI: 10.3322/caac.20107.
[35] H. N. Brad. (2004). IL-2, regulatory T cells, and tolerance. Journal of Immunology.172(7):3983-3988. DOI: 10.3322/caac.20107.
[36] S. Noble, K. L. Goa. (1997). Aldesleukin (recombinant interleukin-2). BioDrugs.7(5):394-422. DOI: 10.3322/caac.20107.
[37] A. Valle, A. Gutiérrez, M. C. Lagunas, B. Weiss. et al.(2016). Pleiotropic effects of IL-2 on cancer: its role in cervical cancer. Mediators of Inflammation.2016-11. DOI: 10.3322/caac.20107.
[38] S. Dasari, P. B. Tchounwou. (2014). Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology.740:364-378. DOI: 10.3322/caac.20107.
[39] R. Pearcey, M. Brundage, P. Drouin. (2002). Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. Journal of Clinical Oncology.20(4):966-972. DOI: 10.3322/caac.20107.
[40] D. Tang, D. Wu, A. Hirao. (2002). ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. Journal of Biological Chemistry.277(15):12710-12717. DOI: 10.3322/caac.20107.
[41] H.-J. Seol, R. Ulak, K.-D. Ki, J.-M. Lee. et al.(2014). Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials. The Tohoku Journal of Experimental Medicine.232(4):269-276. DOI: 10.3322/caac.20107.
[42] X. Castellsagué, M. Díaz, S. de Sanjosé. (2006). Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. JNCI: Journal of the National Cancer Institute.98(5):303-315. DOI: 10.3322/caac.20107.
[43] A. Jemal, F. Bray, M. M. Center, J. Ferlay. et al.(2011). Global cancer statistics. CA: A Cancer Journal for Clinicians.61(2):69-90. DOI: 10.3322/caac.20107.
[44] S. Mueller, M. Schittenhelm, F. Honecker. (2006). Cell-cycle progression and response of germ cell tumors to cisplatin in vitro. International Journal of Oncology.29(2):471-479. DOI: 10.3322/caac.20107.
[45] J. X. Lin, W. J. Leonard. (1997). Signaling from the IL-2 receptor to the nucleus. Cytokine & Growth Factor Reviews.8(4):313-332. DOI: 10.3322/caac.20107.
[46] T. Saito, J. Yoda, T. Tabata. (1991). Local administration trials of interleukin-2 for head and neck cancer. Auris Nasus Larynx.18(2):169-178. DOI: 10.3322/caac.20107.
[47] B. Gao, X. Shen, G. Kunos. (2001). Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Letters.488(3):179-184. DOI: 10.3322/caac.20107.
[48] J. M. Lee, K. B. Lee, C. Y. Park. (2006). Prognostic factors predicting survival in patients with FIGO stage IB cervical cancer treated surgically. International Journal of Gynecology & Obstetrics.94(2):143-144. DOI: 10.3322/caac.20107.
[49] Q. Zhang, I. Nowak, E. C. Vonderheid. (1996). Activation of JAK/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proceedings of the National Academy of Sciences of the United States of America.93(17):9148-9153. DOI: 10.3322/caac.20107.
[50] J. P. Caradonna, S. J. Lippard, M. J. Gait, M. Singh. et al.(1982). The antitumor drug cis-dichlorodiammineplatinum forms an intrastrandd (GpG) crosslink upon reaction with [d(ApGpGpCpCpT)]2. Journal of the American Chemical Society.104(21):5793-5795. DOI: 10.3322/caac.20107.
[51] L. Rocha, C. Huitron, J. R. Caceres. (2004). Interleukin-2 (IL-2) receptor-betagamma signaling is activated by c-Kit in the absence of IL-2, or by exogenous IL-2 via JAK3/STAT5 in human papillomavirus-associated cervical cancer. Cellular Signalling.16(11):1239-1247. DOI: 10.3322/caac.20107.
[52] R. Rangel, T. Corona, I. Soto. (2010). Evidence that cervical cancer cells secrete IL-2, which becomes an autocrine growth factor. Cytokine.50(3):273-277. DOI: 10.3322/caac.20107.
[53] J. A. Pietenpol, Z. A. Stewart. (2002). Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology.181-182:475-481. DOI: 10.3322/caac.20107.
[54] T. Zelante, A. Y. Wong, T. J. Ping. (2015). CD103 dendritic cells control Th17 cell function in the lung. Cell Reports.12(11):1789-1801. DOI: 10.3322/caac.20107.
[55] A. Ray, S. Jena, B. Dash. (2019). Hedychium coronarium extract arrests cell cycle progression, induces apoptosis, and impairs migration and invasion in HeLa cervical cancer cells. Cancer Management and Research.11(11):483-500. DOI: 10.3322/caac.20107.
[56] N. Duale, B. Lindeman, M. Komada. (2007). Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Molecular Cancer.6(1):53. DOI: 10.3322/caac.20107.
[57] M. Shi, K. L. McMillan, J. Wu. (2018). Cisplatin nephrotoxicity as a model of chronic kidney disease. Laboratory Investigation.98(8):1105-1121. DOI: 10.3322/caac.20107.
[58] R. M. González, M. A. Ruiz, Y. Gómez. (2007). Serum levels of interleukin-2 before and after blood donation. Revista Cubana de Hematologia, Inmunologia y Hemoterapia.23(2):1-4. DOI: 10.3322/caac.20107.
[59] S. Zeng, H. S. Wen, L. Liu. (2018). Senescence and cancer. Cancer Translational Medicine.4(3):70-74. DOI: 10.3322/caac.20107.
浏览 22次
下载全文 1次
评分次数 0次
用户评分 0.0分
分享 0次